Two draft guideline documents were issued Tuesday by the FDA requiring pharmaceutical and medtech companies to balance discussion of benefits and risks associated with their products in social media communication. The agency also outlined how companies can address misinformation posted by others about their products. The proposals are open for comment within 90 days.

Full Story:

Related Summaries